Condition: Fabry Disease · Sponsor: Chiesi Farmaceutici S.p.A.
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
This description comes directly from the study's public registry record.
Medical Information Chiesi · (888) 661-9260 · us.medical@chiesi.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
| Infusion Associates | Grand Rapids, Michigan, United States | Recruiting |
| Lysosomal & Rare Disorder Research & Treatment Center (LRDRTC) | Fairfax, Virginia, United States | Recruiting |
| General Hospital Slovenj Gradec | Slovenj Gradec, Slovenia | Recruiting |
| University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital | Edgbaston, Birmingham, United Kingdom | Recruiting |
| Salford Royal | Salford, Greater Manchester, United Kingdom | Recruiting |
| The Royal Free Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06663358